Self-expanding mesh-metal oesophageal stent (SEMS)
DeviceA removable stent designed for the treatment of bleeding oesophageal varices.
Other names: DANIS Stent
NCT Number: NCT01851564
The mortality rates from Acute Variceal Haemorrhage remain significant and first line therapy may fail in 15-25% of patients. The self-expandable metal stent has been described in case series as having a very high efficacy at control of haemorrhage from oesophageal varices when used as rescue therapy. This randomised controlled trial aims to assess for any potential superiority of the stent over 'standard' endoscopic techniques as primary or rescue therapy for bleeding oesophageal varices.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
United Bristol Hospitals NHS Foundation Trust, Bristol, United Kingdom
Despite improvements in recent years, mortality from variceal bleeding remains significant. The routine use of banding ligation, vasoactive drugs, and antibiotics has had an impact on survival rates such that survival rates of patients with Childs-Pugh A and B class cirrhosis may be as high as 90% at 30 days. However, the successful outcome of variceal bleeding is compromised in some patients because of initial failure to control bleeding or early re-bleeding, both of which have a significant impact on mortality.
The SX-Ella Danis stent (Ella-CS, Hradec Kralove, Czech Republic) is a removable, covered, self-expanding mesh-metal stent (SEMS) that can be deployed in the lower oesophagus over an endoscopically placed guidewire without radiological screening. The stent controls bleeding by tamponade of varices in the lower oesophagus.
The series reported to date suggest that the self-expandable covered stents can provide 100% haemostasis rates when applied for refractory oesophageal variceal bleeding. Given the potentially lower risks of re-bleeding and safe, easy insertion techniques the self-expandable covered stents may offer a superior alternative to standard endoscopic therapy.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A removable stent designed for the treatment of bleeding oesophageal varices.
Other names: DANIS Stent
Standard Medical and Endoscopic Therapy
Time frame: 7 days
Failure to control Bleeding (as defined by the Baveno V Criteria) or re-bleeding within 7 days.
Time frame: 14 and 42 days
Time frame: 7, 14, 42 days and 6 months
Time frame: 7 days
for the duration of stent migration
Time frame: 7 days
Time frame: 7 days
Time frame: 7 days
Time frame: Total Length of Intensive Care Unit and Hospital Stay (an average of 3 and 10 days respectively)
Time frame: 7 days
Time frame: 6 months
Time frame: 6 months
University College, London
Other
Effective Haemostasis Using Self-expandable Covered Mesh-metal Oesophageal Stents Versus Standard Endoscopic Therapy in the Treatment of Oesophageal Variceal Haemorrhage: A Multicentre, Open, Prospective, Randomised, Controlled Study.
Acronym: SOV
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01267669
Acute Bleeding Esophageal Varices, Cirrhosis
New Delhi, National Capital Territory of Delhi, India
View Trial DetailsNCT06839352
Digestive System Diseases, Esophageal Diseases
Zagazig, Sharqia Province, Egypt
View Trial DetailsNCT02335580
Cardiovascular Diseases, Digestive System Diseases
Shenyang, Liaoning, China
View Trial DetailsNCT04358016
Acute Kidney Injury, Cirrhosis, Liver
Shanghai, China
View Trial Details